NovaBridge Biosciences American Depositary Shares (NBP)
NASDAQ (NMS) 
Summary
NBP Chart
NovaBridge Biosciences American Depositary Shares Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 1.39M | $5.53M | $2.52M | -$3.01M | -54.5% |
 Li Peng China Universal Asset Management Co. Ltd. | 19,919 | $74,749.54 | $36,850.15 | -$37,899.39 | -50.7% |
| TK Taro Kuriyama Axq Capita LLP | 83,330 | $204,992 | $150,827.3 | -$54,164.7 | -26.42% |
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 25,982 | $64,718.11 | $47,539.27 | -$17,178.84 | -26.54% |
 Raymond Debbane Siren, L.L.C. | 3M | $11.71M | $5.36M | -$6.35M | -54.25% |
NovaBridge Biosciences American Depositary Shares (NBP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has NovaBridge Biosciences American Depositary Shares ever had a stock split?
NovaBridge Biosciences American Depositary Shares Profile
| - Industry | - Sector | Dr. Xi-Yong Fu M.B.A., Ph.D. CEO | NASDAQ (NMS) Exchange | 44975P103 CUSIP |
| United States Country | 30 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
NovaBridge Biosciences American Depositary Shares represent ownership in NovaBridge Biosciences, a biotechnology company founded in 2020 and headquartered in Shanghai, China. This innovative firm specializes in developing advanced precision therapies primarily tailored for oncology and immunology indications. With a commitment to addressing unmet medical needs, NovaBridge focuses on creating groundbreaking treatment options for patients suffering from difficult-to-treat cancers and autoimmune diseases. The company operates by leveraging next-generation technologies and platforms, including proprietary linker-payload systems and tumor-targeted delivery methods, which enhance therapeutic efficacy and minimize toxicity. Through a combination of discovery, preclinical development, and clinical-stage programs, NovaBridge aims to expedite the advancement of its therapeutic pipeline while actively partnering with global pharmaceutical companies to accelerate innovation in the biotechnology sector.
Products and Services
- Antibody-Drug Conjugates (ADCs): NovaBridge is at the forefront of developing next-generation ADCs, which combine antibodies with cytotoxic drugs to deliver targeted therapy directly to cancer cells. This method enhances the effectiveness of cancer treatment while reducing systemic toxicity.
- Bispecific Antibodies: These innovative therapeutics are designed to engage two different antigens simultaneously, potentially leading to more effective treatment strategies for complex diseases such as cancer and autoimmune disorders.
- Protein Degraders: The company is pioneering research in protein degradation technologies aimed at selectively targeting and eliminating disease-causing proteins within cells, which provides a novel therapeutic approach for treating various cancers and immune-related diseases.
- Linker-Payload Technologies: NovaBridge employs proprietary linker-payload systems that enhance the delivery and efficacy of its therapeutics. This technology is crucial in ensuring that the therapeutic compounds reach their intended targets with minimal side effects.
- Tumor-Targeted Delivery Systems: By utilizing advanced delivery systems, NovaBridge aims to improve the localization of therapies at the tumor site, thereby maximizing treatment effectiveness and further reducing overall toxicity for patients.
